Early feasibility data from two studies of valve replacement presented at TCT 2021 show promise for novel transcatheter devices for mitral and tricuspid regurgitation. The Intrepid (Medtronic) ...

The largest study to examine outcomes for patients treated outside a clinical trial setting with a minimally invasive procedure to repair a poorly functioning mitral valve in the heart found that the ...

PHOENIX -- Global experience with the novel Intrepid transapical transcatheter mitral valve replacement (TMVR) device through 2 years showed high risks of mortality and complications, raising concerns ...

Please provide your email address to receive an email when new articles are posted on . Employing intravascular lithotripsy facilitated transcatheter mitral valve replacement in a patient with severe ...

Please provide your email address to receive an email when new articles are posted on . A transcatheter mitral valve replacement system was approved for patients at high surgical risk. The system is ...

Overview The global Transcatheter Mitral Valve Replacement (TMVR) market is witnessing rapid expansion and is expected to grow at a strong CAGR of nearly 20% during the forecast period. The increasing ...

After years of interest in and anticipation about the potential for transcatheter mitral valve replacement (TMVR), Edwards Lifesciences is ready to kick off a CE Mark trial for its TMVR system. The ...

Abbott received a CE mark for a first-of-its-kind transcatheter mitral valve implantation system, aimed at stopping leakage and backflow within the heart when open surgery or minimally invasive repair ...

Two-year outcomes following transcatheter mitral valve replacement with the Tendyne prosthesis showed durable control of mitral regurgitation, sustained improvement in quality of life and functional ...

For patients with degenerated bioprosthetic valves, transcatheter mitral valve-in-valve (MViV) using Sapien 3 (Edwards Lifesciences) provides low rates of mortality and improves heart failure symptoms ...

Their findings on the condition called degenerative mitral regurgitation were published today in the peer-reviewed Journal of the American Medical Association (JAMA), representing the largest study to ...

IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced the company’s SAPIEN M3 mitral valve replacement system is the first transcatheter therapy utilizing a transseptal approach ...